

HÃ©lÃ¨ne Barreteau

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11974564/publications.pdf>

Version: 2024-02-01

42
papers

1,652
citations

394421

19
h-index

302126

39
g-index

42
all docs

42
docs citations

42
times ranked

1855
citing authors

#	ARTICLE	IF	CITATIONS
1	Towards discovery of inhibitors of the undecaprenyl-pyrophosphate phosphatase BacA by virtual high-throughput screening. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 2360-2371.	4.1	3
2	Mur ligases inhibitors with azastilbene scaffold: Expanding the structure-activity relationship. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2021, 40, 127966.	2.2	7
3	The Biology of Colicin M and Its Orthologs. <i>Antibiotics</i> , 2021, 10, 1109.	3.7	6
4	CbrA Mediates Colicin M Resistance in <i>Escherichia coli</i> through Modification of Undecaprenyl-Phosphate-Linked Peptidoglycan Precursors. <i>Journal of Bacteriology</i> , 2020, 202, .	2.2	3
5	Virtual screening approach and biochemical evaluation on MurB. <i>Chemical Data Collections</i> , 2019, 24, 100276.	2.3	2
6	Evaluation of the published kinase inhibitor set to identify multiple inhibitors of bacterial ATP-dependent mur ligases. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2019, 34, 1010-1017.	5.2	12
7	Impact of FiuA Outer Membrane Receptor Polymorphism on the Resistance of <i>Pseudomonas aeruginosa</i> toward Peptidoglycan Lipid II-Targeting Paem Pyocins. <i>Journal of Bacteriology</i> , 2019, 201, .	2.2	2
8	Lipid Intermediates in Bacterial Peptidoglycan Biosynthesis. , 2019, , 217-235.		0
9	In silico identification, synthesis and biological evaluation of novel tetrazole inhibitors of MurB. <i>Chemical Biology and Drug Design</i> , 2018, 91, 1101-1112.	3.2	10
10	A road map for prioritizing warheads for cysteine targeting covalent inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2018, 160, 94-107.	5.5	80
11	Anthranilic Acid Inhibitors of Undecaprenyl Pyrophosphate Synthase (UppS), an Essential Enzyme for Bacterial Cell Wall Biosynthesis. <i>Frontiers in Microbiology</i> , 2018, 9, 3322.	3.5	8
12	Discovery of new MurA inhibitors using induced-fit simulation and docking. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 944-949.	2.2	24
13	Identification and Partial Characterization of a Novel UDP-N-Acetylenolpyruvoylglucosamine Reductase/UDP-N-Acetylmuramate:l-Alanine Ligase Fusion Enzyme from <i>Verrucomicrobium spinosum</i> DSM 4136T. <i>Frontiers in Microbiology</i> , 2016, 7, 362.	3.5	6
14	Pectocin M1 (PcaM1) Inhibits <i>Escherichia coli</i> Cell Growth and Peptidoglycan Biosynthesis through Periplasmic Expression. <i>Antibiotics</i> , 2016, 5, 36.	3.7	5
15	Crystallographic Study of Peptidoglycan Biosynthesis Enzyme MurD: Domain Movement Revisited. <i>PLoS ONE</i> , 2016, 11, e0152075.	2.5	15
16	Unusual substrate specificity of the peptidoglycan MurE ligase from <i>Erysipelothrix rhusiopathiae</i> . <i>Biochimie</i> , 2016, 121, 209-218.	2.6	5
17	Lipid Intermediates in Bacterial Peptidoglycan Biosynthesis. , 2016, , 1-19.		1
18	Furan-based benzene mono- and dicarboxylic acid derivatives as multiple inhibitors of the bacterial Mur ligases (MurC-MurF): experimental and computational characterization. <i>Journal of Computer-Aided Molecular Design</i> , 2015, 29, 541-560.	2.9	21

#	ARTICLE	IF	CITATIONS
19	Design, synthesis and evaluation of second generation MurF inhibitors based on a cyanothiophene scaffold. <i>European Journal of Medicinal Chemistry</i> , 2014, 73, 83-96.	5.5	25
20	Inhibitor Design Strategy Based on an Enzyme Structural Flexibility: A Case of Bacterial MurD Ligase. <i>Journal of Chemical Information and Modeling</i> , 2014, 54, 1451-1466.	5.4	21
21	Deciphering the Metabolism of Undecaprenyl-Phosphate: The Bacterial Cell-Wall Unit Carrier at the Membrane Frontier. <i>Microbial Drug Resistance</i> , 2014, 20, 199-214.	2.0	128
22	Benzene-1,3-dicarboxylic acid 2,5-dimethylpyrrole derivatives as multiple inhibitors of bacterial Mur ligases (MurCâ€“MurF). <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 4124-4134.	3.0	34
23	Synthetic tripeptides as alternate substrates of murein peptide ligase (Mpl). <i>Biochimie</i> , 2013, 95, 1120-1126.	2.6	7
24	Structureâ€“activity relationships of new cyanothiophene inhibitors of the essential peptidoglycan biosynthesis enzyme MurF. <i>European Journal of Medicinal Chemistry</i> , 2013, 66, 32-45.	5.5	62
25	Specificity Determinants for Lysine Incorporation in <i>Staphylococcus aureus</i> Peptidoglycan as Revealed by the Structure of a MurE Enzyme Ternary Complex. <i>Journal of Biological Chemistry</i> , 2013, 288, 33439-33448.	3.4	33
26	MurD enzymes: some recent developments. <i>Biomolecular Concepts</i> , 2013, 4, 539-556.	2.2	28
27	Biochemical characterization of MurF from <i>Streptococcus pneumoniae</i> and the identification of a new MurF inhibitor through ligand-based virtual screening. <i>Acta Chimica Slovenica</i> , 2013, 60, 294-9.	0.6	6
28	Colicin M, a peptidoglycan lipid-II-degrading enzyme: potential use for antibacterial means?. <i>Biochemical Society Transactions</i> , 2012, 40, 1522-1527.	3.4	17
29	Characterization of Colicin M and its Orthologs Targeting Bacterial Cell Wall Peptidoglycan Biosynthesis. <i>Microbial Drug Resistance</i> , 2012, 18, 222-229.	2.0	17
30	Functional and Structural Characterization of PaeM, a Colicin M-like Bacteriocin Produced by <i>Pseudomonas aeruginosa</i> . <i>Journal of Biological Chemistry</i> , 2012, 287, 37395-37405.	3.4	33
31	MurD enzymes from different bacteria: Evaluation of inhibitors. <i>Biochemical Pharmacology</i> , 2012, 84, 625-632.	4.4	20
32	Colicin M hydrolyses branched lipids II from Gram-positive bacteria. <i>Biochimie</i> , 2012, 94, 985-990.	2.6	15
33	The Binding Mode of Second-Generation Sulfonamide Inhibitors of MurD: Clues for Rational Design of Potent MurD Inhibitors. <i>PLoS ONE</i> , 2012, 7, e52817.	2.5	12
34	Second-generation sulfonamide inhibitors of d-glutamic acid-adding enzyme: Activity optimisation with conformationally rigid analogues of d-glutamic acid. <i>European Journal of Medicinal Chemistry</i> , 2011, 46, 2880-2894.	5.5	51
35	X-Ray Structure and Site-Directed Mutagenesis Analysis of the <i>Escherichia coli</i> Colicin M Immunity Protein. <i>Journal of Bacteriology</i> , 2011, 193, 205-214.	2.2	21
36	Deciphering the Catalytic Domain of Colicin M, a Peptidoglycan Lipid II-degrading Enzyme. <i>Journal of Biological Chemistry</i> , 2010, 285, 12378-12389.	3.4	36

#	ARTICLE	IF	CITATIONS
37	Toxicity of the Colicin M Catalytic Domain Exported to the Periplasm Is FkpA Independent. <i>Journal of Bacteriology</i> , 2010, 192, 5212-5219.	2.2	16
38	Purification and biochemical characterization of Mur ligases from <i>Staphylococcus aureus</i> . <i>Biochimie</i> , 2010, 92, 1793-1800.	2.6	28
39	Human- and Plant-Pathogenic <i>Pseudomonas</i> Species Produce Bacteriocins Exhibiting Colicin M-Like Hydrolase Activity towards Peptidoglycan Precursors. <i>Journal of Bacteriology</i> , 2009, 191, 3657-3664.	2.2	68
40	Quantitative high-performance liquid chromatography analysis of the pool levels of undecaprenyl phosphate and its derivatives in bacterial membranes. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2009, 877, 213-220.	2.3	75
41	Cytoplasmic steps of peptidoglycan biosynthesis. <i>FEMS Microbiology Reviews</i> , 2008, 32, 168-207.	8.6	583
42	Colicin M Exerts Its Bacteriolytic Effect via Enzymatic Degradation of Undecaprenyl Phosphate-linked Peptidoglycan Precursors. <i>Journal of Biological Chemistry</i> , 2006, 281, 22761-22772.	3.4	106